Working Together to Lower A1c

*If diet and excercise plus monotherapy with Actos, Avandia, metformin, SFUs, or PRANDIN^® does not result in adequate glycemic control, combination therapy can be used. If hypoglycemia occurs in patients taking a combination of PRANDIN^® and any sensitizer, the dose of PRANDIN^® should be reduced.

†Prior to combination therapy, patients were not satisfactorily controlled on SFU or metformin monotherapy for at least 3 months.

‡There were 246 patients in the PRANDIN^®/Actos study and 252 patients in the PRANDIN^®/Avandia study.⁴

In the thiazolidinedione (TZD) combination studies hypoglycemia occurred in 7% of patients on combination therapy, 7% of patients treated with PRANDIN^® alone, and 2% of patients treated with TZD alone.When adjusted for dropout rates, the percentages of patients having peripheral edema per 24 weeks of treatment were 5% for PRANDIN^®/TZD combination therapy and 4% for TZD monotherapy. No peripheral edema was reported for those who received PRANDIN^® monotherapy. Two patients, both with coronary artery disease history, reported edema with congestive heart failure; none were reported from the monotherapy groups. Mean weight change was +4.9 kg for PRANDIN^®/TZD combination therapy. In 1-year clinical trials, the most common adverse events leading to discontinuation of PRANDIN^® therapy were hyperglycemia, hypoglycemia, and related symptoms.

References:

1. Jovanovic L, Jain R, Greco S, Hale P, Khutoryansky N, Santiago O. Repaglinide/pioglitazone combination therapy of type 2 diabetes. Diabetes. 2001;50(Suppl 2):A439.
2. Data on file, Novo Nordisk Pharmaceuticals, Inc.
3. Raskin P, McGill J, Hale P, Khutoryansky N, Santiago O. Repaglinide/rosiglitazone combination therapy of type 2 diabetes. Diabetes. 2001;50(Suppl 2):A128.
4. Prandin^® Prescribing Information, Novo Nordisk Pharmaceuticals, Inc.
5. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999;22:119-124.

PRANDIN® is a registered trademark of Novo Nordisk A/S. Actos is a registered trademark of Takeda Chemical Industries, Ltd and is used under license by Takeda Pharmaceuticals North America, Inc and Eli Lilly and Company. Avandia is a registered trademark of GlaxoSmithKline.

Please see brief summary of full Prescribing Information.